GF Fund Management CO. LTD. Invests $420,000 in Hologic, Inc. (NASDAQ:HOLX)

GF Fund Management CO. LTD. purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,830 shares of the medical equipment provider's stock, valued at approximately $420,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Barclays PLC raised its stake in shares of Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after buying an additional 231,578 shares during the period. LaFleur & Godfrey LLC increased its holdings in Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock worth $9,399,000 after acquiring an additional 3,655 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after acquiring an additional 19,688 shares during the period. Sound Income Strategies LLC purchased a new position in Hologic during the fourth quarter valued at $60,000. Finally, Exchange Traded Concepts LLC lifted its holdings in Hologic by 5.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 20,764 shares of the medical equipment provider's stock valued at $1,497,000 after purchasing an additional 1,115 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Trading Down 1.2%

Shares of Hologic stock traded down $0.79 during mid-day trading on Thursday, hitting $62.92. The stock had a trading volume of 3,693,225 shares, compared to its average volume of 2,249,872. The firm has a 50-day moving average of $58.09 and a two-hundred day moving average of $66.21. The firm has a market cap of $14.02 billion, a P/E ratio of 19.85, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the business posted $1.03 earnings per share. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on HOLX. Morgan Stanley decreased their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Finally, Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.